Beacon reposted this
2024 Pipeline Review for Hot Modalities! No better time of year to take a look into the data across 2024 and how landscape dynamics have evolved… I have collected some stats & thoughts on some of the high growth modalities we have custom databases for at Beacon. In terms of new trials initiated and the current state of play at preclinical levels, ADC, Bispecifics, Cell Therapies & RNA therapies lead the way here. On top of these 4 areas, there are reasons to be excited in other modalities looking at 2025. · Gene Therapy A challenging year for the space finished with positive outlooks for 2025, with Novartis’ acquisition of Kate Therapeutics & GEMMABio’s $35m Seed funding demonstrating there is still a place at the table for AAV gene therapies A mixed bag for gene editing with advances made for in vivo base editing and several deals for epigenome editing earlier in the year – it’s clear the field is evolving and could see a strong 2025 · TPD An exciting year again as we enter a crucial time for the future of the protein degrader space, with increasing clinical validation of degraders as a mechanism of action. TPD companies have begun looking at diversifying their pipelines into to induced proximity to investigate modification as well as down/upregulation of proteins. One key theme we identified in 2024 brings learnings from the ADC space in the degrader landscape, with cutting edge research to enhance targeted delivery to tissues of interest via antibody-degrader conjugates as a new modality · Cancer Vaccines mRNA cancer vaccines are growing in interest for personalized medicines with 32 new trials in 2024. 2025 will be an important year for the future of these therapies with patients now being recruited for Merck/Moderna’s Keytruda combination trial Definitely missed some other exciting modalities and nuances from other high growth areas in here – would be keen to hear what else people are excited about! #RNA #Genetherapy #ADC #Bispecific #CancerVaccine #TPD #Celltherapy